Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582359 · ClinicalTrials.gov registry record · Phase 1
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT02582359: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT02582359 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02582359, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin and cytarabine as a possible treatment for the patient AML.
Interventions
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG MLN9708
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-01 |
| Est. Completion | 2022-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02582359
The ClinicalTrials.gov registry entry for NCT02582359 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cytarabine is the first listed.
NCT02582359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02582359 about?
NCT02582359 is a clinical study titled "MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age". This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin and cytarabine as a possible treatment for the patient AML.
What is the current status of trial NCT02582359?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2016-01. Estimated completion is 2022-04.
What interventions are being tested in trial NCT02582359?
The interventions under investigation include: Cytarabine (DRUG), Daunorubicin (DRUG), MLN9708 (DRUG).
Who is sponsoring clinical trial NCT02582359?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.